P/E ratio for KemPharm (KMPH)
P/E ratio as of May 2024 (TTM): -5.87
According to KemPharm's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -5.86869. At the end of 2016 the company had a P/E ratio of -2.44.
P/E ratio history for KemPharm from 2015 to 2022
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2016 | -2.44 | -47.76% |
| 2015 | -4.67 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 Theravance Biopharma
TBPH | 0.7430 | -112.66% | Cayman Islands |
 Jazz Pharmaceuticals JAZZ | -78.5 | 1,238.39% | 🇮🇪 Ireland |
 ANI Pharmaceuticals ANIP | -140 | 2,292.80% | 🇺🇸 USA |
 Agile Therapeutics
AGRX | -0.0112 | -99.81% | 🇺🇸 USA |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.